755 related articles for article (PubMed ID: 30033370)
1. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA; Dang HX; Zhao SG; Lloyd P; Aggarwal R; Alumkal JJ; Foye A; Kothari V; Perry MD; Bailey AM; Playdle D; Barnard TJ; Zhang L; Zhang J; Youngren JF; Cieslik MP; Parolia A; Beer TM; Thomas G; Chi KN; Gleave M; Lack NA; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Ryan CJ; Fong L; Kim W; Friedlander T; Chou J; Li H; Das R; Li H; Moussavi-Baygi R; Goodarzi H; Gilbert LA; Lara PN; Evans CP; Goldstein TC; Stuart JM; Tomlins SA; Spratt DE; Cheetham RK; Cheng DT; Farh K; Gehring JS; Hakenberg J; Liao A; Febbo PG; Shon J; Sickler B; Batzoglou S; Knudsen KE; He HH; Huang J; Wyatt AW; Dehm SM; Ashworth A; Chinnaiyan AM; Maher CA; Small EJ; Feng FY
Cell; 2018 Jul; 174(3):758-769.e9. PubMed ID: 30033370
[TBL] [Abstract][Full Text] [Related]
2. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
[TBL] [Abstract][Full Text] [Related]
3. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
van Dessel LF; van Riet J; Smits M; Zhu Y; Hamberg P; van der Heijden MS; Bergman AM; van Oort IM; de Wit R; Voest EE; Steeghs N; Yamaguchi TN; Livingstone J; Boutros PC; Martens JWM; Sleijfer S; Cuppen E; Zwart W; van de Werken HJG; Mehra N; Lolkema MP
Nat Commun; 2019 Nov; 10(1):5251. PubMed ID: 31748536
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
[TBL] [Abstract][Full Text] [Related]
5.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
7. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA.
Grad JM; Dai JL; Wu S; Burnstein KL
Mol Endocrinol; 1999 Nov; 13(11):1896-911. PubMed ID: 10551783
[TBL] [Abstract][Full Text] [Related]
8. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
[TBL] [Abstract][Full Text] [Related]
10. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
Vander Griend DJ; Litvinov IV; Isaacs JT
Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
[TBL] [Abstract][Full Text] [Related]
11. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
[TBL] [Abstract][Full Text] [Related]
12. Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs.
Hadi K; Yao X; Behr JM; Deshpande A; Xanthopoulakis C; Tian H; Kudman S; Rosiene J; Darmofal M; DeRose J; Mortensen R; Adney EM; Shaiber A; Gajic Z; Sigouros M; Eng K; Wala JA; Wrzeszczyński KO; Arora K; Shah M; Emde AK; Felice V; Frank MO; Darnell RB; Ghandi M; Huang F; Dewhurst S; Maciejowski J; de Lange T; Setton J; Riaz N; Reis-Filho JS; Powell S; Knowles DA; Reznik E; Mishra B; Beroukhim R; Zody MC; Robine N; Oman KM; Sanchez CA; Kuhner MK; Smith LP; Galipeau PC; Paulson TG; Reid BJ; Li X; Wilkes D; Sboner A; Mosquera JM; Elemento O; Imielinski M
Cell; 2020 Oct; 183(1):197-210.e32. PubMed ID: 33007263
[TBL] [Abstract][Full Text] [Related]
13. The DNA methylation landscape of advanced prostate cancer.
Zhao SG; Chen WS; Li H; Foye A; Zhang M; Sjöström M; Aggarwal R; Playdle D; Liao A; Alumkal JJ; Das R; Chou J; Hua JT; Barnard TJ; Bailey AM; Chow ED; Perry MD; Dang HX; Yang R; Moussavi-Baygi R; Zhang L; Alshalalfa M; Laura Chang S; Houlahan KE; Shiah YJ; Beer TM; Thomas G; Chi KN; Gleave M; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Yvonne Kim M; Fong L; Spratt DE; Morgan TM; Bose R; Huang FW; Li H; Chesner L; Shenoy T; Goodarzi H; Asangani IA; Sandhu S; Lang JM; Mahajan NP; Lara PN; Evans CP; Febbo P; Batzoglou S; Knudsen KE; He HH; Huang J; Zwart W; Costello JF; Luo J; Tomlins SA; Wyatt AW; Dehm SM; Ashworth A; Gilbert LA; Boutros PC; Farh K; Chinnaiyan AM; Maher CA; Small EJ; Quigley DA; Feng FY
Nat Genet; 2020 Aug; 52(8):778-789. PubMed ID: 32661416
[TBL] [Abstract][Full Text] [Related]
14. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
[TBL] [Abstract][Full Text] [Related]
15. Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
Sienkiewicz K; Yang C; Paschal BM; Ratan A
Prostate; 2022 Mar; 82(4):442-451. PubMed ID: 34951700
[TBL] [Abstract][Full Text] [Related]
16. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
17. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
18. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
19. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.
Kumar A; White TA; MacKenzie AP; Clegg N; Lee C; Dumpit RF; Coleman I; Ng SB; Salipante SJ; Rieder MJ; Nickerson DA; Corey E; Lange PH; Morrissey C; Vessella RL; Nelson PS; Shendure J
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17087-92. PubMed ID: 21949389
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
